Prokarium is a clinical-stage biopharmaceutical company headquartered in London, UK, developing bacterial immunotherapies for solid tumors. Its foundational technology uses a proprietary attenuated strain of Salmonella enterica serovar Typhi (ZH9) as a microbial immunotherapy platform that is naturally tumor-targeting and oncolytic, designed to overcome the suppressive tumor microenvironment and generate anti-tumor immune responses while enabling diverse cargo delivery. The lead program, ZH9 for non-muscle invasive bladder cancer, is in the Phase 1/1b PARADIGM-1 trial, with a muscle-invasive bladder cancer combination arm alongside checkpoint inhibitors, an oral immune fitness agent (IO Prime), and a discovery-stage Living Cures cargo-delivery platform. Prokarium is a therapeutics developer, not a software or data company, and publishes no public API, SDK, developer portal or machine-readable interface of any kind.
Prokarium is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Immunotherapy.
Prokarium’s developer surface includes engineering blog and 3 more developer resources.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/prokarium: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: prokarium
name: Prokarium
description: Prokarium is a clinical-stage biopharmaceutical company headquartered in London, UK, developing bacterial immunotherapies
for solid tumors. Its foundational technology uses a proprietary attenuated strain of Salmonella enterica serovar Typhi
(ZH9) as a microbial immunotherapy platform that is naturally tumor-targeting and oncolytic, designed to overcome the suppressive
tumor microenvironment and generate anti-tumor immune responses while enabling diverse cargo delivery. The lead program,
ZH9 for non-muscle invasive bladder cancer, is in the Phase 1/1b PARADIGM-1 trial, with a muscle-invasive bladder cancer
combination arm alongside checkpoint inhibitors, an oral immune fitness agent (IO Prime), and a discovery-stage Living Cures
cargo-delivery platform. Prokarium is a therapeutics developer, not a software or data company, and publishes no public
API, SDK, developer portal or machine-readable interface of any kind.
url: https://raw.githubusercontent.com/api-evangelist/prokarium/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
deliveryModel:
model: unknown
open_source: false
commercial: false
callable_host: false
label: Delivery model not determined — needs a product licence on record
confidence: low
source:
- none
generated: '2026-08-28'
method: derived
accessModel:
pricing: unknown
onboarding: unknown
trial: false
try_now: false
public: false
label: Unknown
confidence: low
source:
- security
generated: '2026-09-02'
method: derived
specificationVersion: '0.20'
created: '2026-08-26'
modified: '2026-08-26'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Immunotherapy
- Oncology
- Synthetic Biology
- Clinical Trials
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: DomainSecurity
url: security/prokarium-domain-security.yml
- type: Website
url: https://www.prokarium.com/
- type: PrivacyPolicy
url: https://www.prokarium.com/privacy
- type: Blog
url: https://www.prokarium.com/news
x-enrichment:
date: '2026-08-26'
status: minimal
artifacts_added: 2
pass: local-v1
x-coverage:
state: none
reason: not-a-software-company
detail: Prokarium is a clinical-stage biopharmaceutical company developing the ZH9 bacterial immunotherapy for bladder cancer;
its entire 96-URL sitemap is corporate, pipeline and press-release pages with no developer, docs, API or data section,
and github.com/prokarium returns 404, so there is no software product for an API to sit behind.
evidence:
- url: https://www.prokarium.com/openapi.json
status: 404
- url: https://www.prokarium.com/.well-known/agent-card.json
status: 404
- url: https://www.prokarium.com/llms.txt
status: 404
- url: https://github.com/prokarium
status: 404
- url: https://www.prokarium.com/sitemap.xml
status: 200
checked: '2026-08-26'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.